Full Event Guide
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at: info@hansonwade.com
Take a look at what the meeting explored:
Exclusive learnings from biopharma demonstrating significant success and companies on the verge of unravelling DDR networks
Critically evaluated biomarker discovery accelerating translational development and improving patient selection for mono or combination therapies
Maximised experiences through a dedicated spotlight to novel targets including PKMYT1, USP1, PARG, and CDC7, all the way from discovery to clinical updates
Having trouble downloading the brochure? Let us know and we’ll email it to you instead
Browse the Full Event Guide to Discover what the Summit Saw:
5 Case Studies of clinical updates from Merck, IDEAYA, Debiopharm, Dana-Farber Cancer Institute and Schrödinger
Novel Insights from pioneering companies including Pfizer’s discovery work to identify new DDR targets and Genentech’s predictive biomarkers for monotherapies
Pharmacological insights from EMD Serono and Accent Therapeutics for dose optimization and early intervention
The Latest Developments across discovery to clinical updates for new targets including WEE1, USP1, CHK1, CDC7, PKMYT1, PARG, and many more
The Definitive Forum to discuss factors determining the perfect DDR target and inhibitor and how to leverage clinical success to prioritise patient support
Companies on the 2024 Program:
